Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece

Table 9

Overall survival and overall progression-free survival according to second-line chemotherapy regimen in the overall population and the group of patients diagnosed during study enrolment.

	Median	95% CI	value
OS (months)
Sequence 1	20.0	8.7–31.4	0.523
Sequence 2	20.2	10.0–30.5
Sequence 3	13.1	10.8–15.3
Sequence 4	13.6	7.6–19.7
PFS (months)
Sequence 1	18.1	6.3–29.9	0.128
Sequence 2	20.4	15.2–25.7
Sequence 3	11.9	9.0–14.8
Sequence 4	10.3	7.1–13.5

Sequence 1 (N = 22): nab-paclitaxel/gemcitabine as first-line followed by FOLFIRINOX/XELOXIRI as second-line treatment. Sequence 2 (N = 19): nab-paclitaxel/gemcitabine as first-line followed by FOLFOX/CAPOX as second-line treatment. Sequence 3 (N = 14): nab-paclitaxel/gemcitabine as first-line followed by other regimens as second-line treatment. Sequence 4 (N = 14): FOLFIRINOX/CAPOXIRI as first-line followed by nab-paclitaxel/gemcitabine as second-line treatment; 95% CI, 95% confidence intervals; OS, overall survival; PFS, progression-free survival.